CollPlant Biotechnologies (CLGN) Downgraded by Zacks Investment Research to Sell

CollPlant Biotechnologies stock has undergone multiple analysts rating changes in the recent past.  CollPlant Biotechnologies Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of CollPlant Biotechnologies traded down -$0.49 on Wednesday, reaching $16.40. 8035 shares of the stock traded hands, compared to its average volume of 10477. Shares of CollPlant Biotechnologies were trading at $16.40 on Wednesday. The firm’s 50 day moving average is $17.27 and its 200 day moving average is $16.28.CollPlant Biotechnologies has a 12 month low of $16.25 and a 12 month high of $24.26. While on yearly highs and lows, CollPlant Biotechnologies’s today has traded high as $17.00 and has touched $16.25 on the downward trend. See More Analyst Rating at: RATING

CollPlant Biotechnologies Earnings and What to expect: 

CollPlant Biotechnologies last announced its quarterly earnings results on August 18th, 2021. The reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.20. The company earned $0.69 million during the quarter, compared to analysts’ expectations of $3.11 million. CollPlant Biotechnologies has generated ($0.84) earnings per share over the last year ($0.23 diluted earnings per share) and currently has a price-to-earnings ratio of 72.1. Earnings for CollPlant Biotechnologies are expected to grow by 850.00% in the coming year, from $0.20 to $1.90 per share. CollPlant Biotechnologies has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, December 7th, 2021 based off prior year’s report dates.

Earnings for CollPlant Biotechnologies are expected to grow by 850.00% in the coming year, from $0.20 to $1.90 per share. The P/E ratio of CollPlant Biotechnologies is 72.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.72. The P/E ratio of CollPlant Biotechnologies is 72.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 32.14. CollPlant Biotechnologies has a P/B Ratio of 20.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

CollPlant Biotechnologies (CLGN) Moving Average Technical Analysis

5 day Moving Average is $16.57 And 5 day price change is $0.44 (2.75%)  with average volume for 5 day average is 7,260. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $16.53 and 20 day price change is -$0.41 (-2.41%) and average 20 day moving volume is 9,935. 50 day moving average is $17.27  and 50 day price change is -$0.73 ( -4.22%)  and with average volume for 50 days is : 13,938. 200 day moving average is $16.28  and 200 day price change is $6.02 (57.01%)  and with average volume for 200 days is : 66,006.

Other owners latest trading in CollPlant Biotechnologies :

  • On 8/17/2021 shares held by Citadel Advisors LLC were 13,034 which equates to market value of $0.28M and appx 0.00% owners of CollPlant Biotechnologies
  • On 8/16/2021 shares held by State Street Corp were 176,490 which equates to market value of $3.74M and appx 0.00% owners of CollPlant Biotechnologies
  • On 8/6/2021 shares held by Parallel Advisors LLC were 4,299 which equates to market value of $91K and appx 0.00% owners of CollPlant Biotechnologies
  • In total Institutional ownership equates to Institutional Ownership Percentage: 9.74% for CollPlant Biotechnologies

See More Analyst Rating at: RATING